BBIO

BBIO

USD

BridgeBio Pharma Inc. Common Stock

$61.000-0.420 (-0.684%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$61.420

उच्च

$61.905

कम

$60.230

मात्रा

2.10M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

11.8B

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

2.63M

एक्सचेंज

NMS

मुद्रा

USD

52-सप्ताह रेंज

कम $21.72वर्तमान $61.000उच्च $69.48

संबंधित समाचार

GlobeNewswire

BridgeBio to Participate in November Investor Conferences

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that

और देखें
BridgeBio to Participate in November Investor Conferences
GlobeNewswire

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten

और देखें
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $90 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma with a Buy and maintains $90 price target.

और देखें
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $90 Price Target
Analyst Upgrades

Goldman Sachs Maintains Buy on BridgeBio Pharma, Raises Price Target to $100

Goldman Sachs analyst Paul Choi maintains BridgeBio Pharma with a Buy and raises the price target from $55 to $100.

और देखें
Goldman Sachs Maintains Buy on BridgeBio Pharma, Raises Price Target to $100
Analyst Upgrades

TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $95

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma with a Buy and raises the price target from $60 to $95.

और देखें
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $95
Analyst Upgrades

Raymond James Reiterates Outperform on BridgeBio Pharma, Raises Price Target to $71

Raymond James analyst Martin Auster reiterates BridgeBio Pharma with a Outperform and raises the price target from $69 to $71.

Analyst Upgrades

Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $110

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma with a Overweight and raises the price target from $100 to $110.

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।